Monitoring Hypothyroidism on Levothyroxine
Monitor serum TSH 4-8 weeks after initiating levothyroxine or any dose change, then every 6 months initially, and annually once stable on an appropriate dose. 1
Initial Monitoring Protocol
After starting levothyroxine or changing the dose, check serum TSH at 4-8 weeks 1, 2. This timing is critical because:
- TSH levels may decline within a month with higher doses (50-75 µg), but smaller dose adjustments may require 8 weeks or longer before TSH plateaus 1
- The FDA label confirms this 6-8 week interval for adults with primary hypothyroidism 2
Make dose adjustments in increments of 12.5-25 µg daily, though even smaller changes may be necessary to achieve goal TSH levels 1.
Long-Term Monitoring Schedule
Once an adequate replacement dose is established, repeat TSH testing at 6-month intervals, then annually 1. The FDA label specifies evaluating clinical and biochemical response every 6-12 months in stable patients 2.
Some experts advocate for more frequent testing to ensure compliance, though the consensus guideline supports the 6-month then annual approach 1.
Special Populations Requiring Different Monitoring
Pregnant Patients
Monitor TSH every 4 weeks during the first half of pregnancy and at least once between 26-32 weeks gestation 1. Pregnancy dramatically increases levothyroxine requirements, and inadequate treatment risks fetal neurodevelopment.
- Goal TSH: <2.5 mIU/L in first trimester, <3.0 mIU/L in second trimester, <3.5 mIU/L in third trimester 1, 2
- After delivery, immediately reduce to pre-pregnancy dose and recheck TSH 4-8 weeks postpartum 2
Pediatric Patients
Monitor TSH and total or free-T4 at 2 and 4 weeks after treatment initiation, 2 weeks after any dose change, then every 3-12 months until growth is completed 2. More frequent monitoring is needed if compliance is poor or values are abnormal.
Patients on Interfering Medications
Recheck TSH within 4-8 weeks when starting or stopping drugs that affect levothyroxine bioavailability or metabolism 1. This includes medications like:
- Proton pump inhibitors, calcium, iron supplements (decrease absorption)
- Estrogen, tamoxifen (increase binding proteins)
- Rifampin, carbamazepine, phenytoin (increase metabolism)
- Amiodarone, beta-blockers (affect peripheral conversion) 1
Continue testing every 4-8 weeks until stable euthyroid indices are documented on the same levothyroxine dose 1.
What to Monitor
TSH is the primary monitoring parameter for primary hypothyroidism 1, 2. Do not target specific TSH values within the normal reference range (except in pregnancy) 1.
For central (secondary/tertiary) hypothyroidism, monitor free-T4 instead of TSH, maintaining levels in the upper half of the normal range 1, 2. TSH is unreliable in these patients due to pituitary/hypothalamic dysfunction.
Common Pitfalls to Avoid
Do not check TSH too early after dose changes—wait the full 4-8 weeks to allow steady-state levels 1. Premature testing leads to inappropriate dose adjustments.
Persistent abnormal TSH despite apparent adequate dosing suggests:
- Poor compliance (most common)
- Malabsorption (taking with food, coffee, or interfering medications)
- Drug interactions
- Progression of underlying thyroid disease 2
Before increasing the dose, verify compliance, timing of administration (30-60 minutes before breakfast or 4 hours after last meal), and absence of interfering substances 1.
Patients on higher levothyroxine doses (>100 µg) have increased risk of suboptimal treatment—nearly 25% develop out-of-range TSH within 6 months, and this exceeds 45% in patients taking >150 µg 3. Consider more frequent monitoring in these patients, particularly if medically complex.
Clinical Context
Some hypothyroid symptoms like chronic skin changes may take 3-6 months to resolve even after TSH normalizes 1. Don't prematurely increase doses based on persistent symptoms if TSH is at goal.
Annual monitoring is sufficient for most stable patients, but check more frequently if there are changes in clinical status, significant weight changes, or new medications 2. The goal is preventing both undertreatment (cardiovascular risk, symptoms) and overtreatment (atrial fibrillation, bone loss, cardiovascular mortality).